Development of a novel combination immunotherapy with NKT cells and antibody therapy

• Project/Area Number: 26861119
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory surgery
• Research Institution: Tokyo Women's Medical University (2015-2016); Chiba University (2014)
• Principal Investigator: Kamata Toshiko 東京女子医科大学, 医学部, 助教 (60586692)
• Research Collaborator: MOTOHASHI Shinichiro 千葉大学, 大学院医学研究院・免疫細胞医学, 教授 (60345022)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: NKT細胞治療 / 抗PDL1抗体 / 癌免疫治療 / NKT細胞 / PD-1

Outline of Final Research Achievements

There are few researches on the function of PD-1/PDL1 in human NKT cells. In our research, we found that PD-1 was upregulated in activated NKT cells and NKT cells derived from lung cancer patients.
Cytokine secretion and anti-tumor functions of NKT cells improved when the ligand for PD-1 (PDL1) was blocked on antigen presenting cells and tumor cells. We also found that these NKT cells improved anti-tumor immunity through interaction with other immune cells. Our results imply that the combination of anti-PD-1/PDL1 with NKT cell-mediated immunotherapy would improve the treatment outcomes in cancer patients. These data may become the basis for future clinical trials.

Research Products

• [Journal Article] Blockade of Programmed Death-1/Programmed Death Ligand pathway enhances the antitumor immunity of human invariant Natural Killer T cells. (2016)
  • Author(s): Kamata T, Suzuki A, Mise N, Ihara F, Takami T, Makita Y, Horinaka A, Harada K, Kunii K, Yoshida S, Yoshino I, Nakayama T, and Motohashi S.
  • Journal Title: Cancer Immunol Immunother. Volume: 65 Issue: 12 Pages: 1477-1489
  • DOI: 10.1007/s00262-016-1901-y
  • Peer Reviewed / Open Access
• [Journal Article] Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells. (2016)
  • Author(s): Mise N, Takami M, Suzuki A, Kamata T, Harada K, Hishiki T, Saito T, Terui K, Mitsunaga T, Nakata M, Ikeuchi T, Nakayama T, Yoshida H, Motohashi S
  • Journal Title: Cancer Science Volume: 107 Issue: 3 Pages: 233-241
  • DOI: 10.1111/cas.12882
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Presentation] Blockade of PD-1/PDL1 in iNKT cell mediated antitumor immunity (2015)
  • Author(s): Toshiko Kamata, Akane Suzuki, Naoko Mise, Yuji Makita, Atsushi Horinaka, Naoki Kunii, Shigetoshi Yoshida, Ichiro Yoshino, Toshinori Nakayama, Shinichiro Motohashi
  • Organizer: 第44回日本免疫学会学術集会
  • Place of Presentation: 札幌コンベンションセンター(北海道札幌市)
  • Year and Date: 2015-11-19
• [Presentation] Blockade of Programmed Death-1/Programmed Death Ligand pathway enhances the antitumor immunity of human invariant Natural Killer T cells (2015)
  • Author(s): Toshiko Kamata, Akane Suzuki, Yuji Makita, Naoki Kunii, Toshinori Nakayama, Shinichiro Motohashi
  • Organizer: 第19回日本がん免疫学会総会
  • Place of Presentation: 伊藤国際学術研究センター(東京都文京区本郷)
  • Year and Date: 2015-07-09
• [Presentation] 原発性肺癌に対するNKT細胞免疫治療と抗PD-1/PD-L1抗体併用療法の有用性 (2015)
  • Author(s): 鎌田稔子、鈴木 茜、吉田成利、吉野一郎、中山俊憲、本橋新一郎
  • Organizer: 千葉医学会
  • Place of Presentation: 千葉県千葉市
  • Year and Date: 2015-02-07
• [Presentation] 原発性肺癌に対するNKT細胞免疫療法におけるPD-1阻害の有用性 (2014)
  • Author(s): 鎌田稔子、鈴木 茜、藤川陽、三瀬直子、蒔田勇治、吉田成利、鈴木秀海、中島崇裕、岩田剛和、吉野一郎、中山俊憲、本橋新一郎
  • Organizer: 日本肺癌学会
  • Place of Presentation: 京都府 国立京都国際会館
  • Year and Date: 2014-11-15
• [Presentation] 原発性肺癌患者における NKT 細胞免疫治療と PD-1 阻害療法の有用性 (2014)
  • Author(s): 鎌田稔子、本橋新一郎、吉田成利、鈴木秀海、中島崇裕、田川哲三、岩田剛和、溝渕輝明、吉野一郎
  • Organizer: 日本呼吸器外科学会
  • Place of Presentation: 東京都 ホテル日航東京
  • Year and Date: 2014-05-29